TY - JOUR
T1 - Small left ventricle and clinical outcomes after transcatheter aortic valve replacement
AU - Saito, Tetsuya
AU - Inohara, Taku
AU - Yoshijima, Nobuhiro
AU - Yashima, Fumiaki
AU - Tsuruta, Hikaru
AU - Shimizu, Hideyuki
AU - Fukuda, Keiichi
AU - Naganuma, Toru
AU - Mizutani, Kazuki
AU - Yamawaki, Masahiro
AU - Tada, Norio
AU - Yamanaka, Futoshi
AU - Shirai, Shinichi
AU - Tabata, Minoru
AU - Ueno, Hiroshi
AU - Takagi, Kensuke
AU - Watanabe, Yusuke
AU - Yamamoto, Masanori
AU - Hayashida, Kentaro
N1 - Funding Information:
The OCEAN-TAVI (Optimized Transcatheter Valvular Intervention– Transcatheter Aortic Valve Implantation) registry is supported by Edwards Lifesciences, Medtronic, Boston Scientific, and Daiichi-Sankyo Company.
Publisher Copyright:
© 2021 The Authors.
PY - 2021
Y1 - 2021
N2 - BACKGROUND: In patients undergoing transcatheter aortic valve replacement (TAVR), those with small left ventricle (LV) may have an increased risk of poor outcomes, because small LV is associated with low-flow (LF), left ventricular hypertrophy. However, the impact of small LV on patients undergoing TAVR remains unknown. METHODS AND RESULTS: We examined 2584 patients who underwent TAVR between October 2013 and May 2017 using data from the Japanese multicenter registry. On the basis of the American Society of Echocardiography guidelines, small LV was defined as left ventricular end-diastolic dimension <42.0 mm for men or <37.8 mm for women. The 2-year clinical outcomes were compared between patients with and without small LV using multivariable Cox regression analyses and propensity score matching. Subgroup analyses by LF, left ventricular hypertrophy were performed. Of 2584 patients who underwent TAVR, 466 (18.0%) had small LV. Patients with small LV had smaller body size and less comorbidity, and were more likely to have LF status compared with those without. Small LV was associated with a higher 2-year all-cause (20.8% versus 14.3%; adjusted hazard ratio [HR],1.58 [95% CI, 1.20–2.09]; P=0.0013) and cardiovascular mortality (8.8% versus 5.5%; adjusted HR, 1.93 [95% CI, 1.25–2.98]; P=0.0028). Propensity score matching analysis showed consistent findings. In subgroup analyses, LF, left ventricular hypertrophy did not interact with small LV. CONCLUSIONS: Small LV, determined by a simple echocardiographic parameter, was associated with poorer clinical outcomes after TAVR regardless of LF, left ventricular hypertrophy. LV size may be useful for assessing clinical outcomes after TAVR.
AB - BACKGROUND: In patients undergoing transcatheter aortic valve replacement (TAVR), those with small left ventricle (LV) may have an increased risk of poor outcomes, because small LV is associated with low-flow (LF), left ventricular hypertrophy. However, the impact of small LV on patients undergoing TAVR remains unknown. METHODS AND RESULTS: We examined 2584 patients who underwent TAVR between October 2013 and May 2017 using data from the Japanese multicenter registry. On the basis of the American Society of Echocardiography guidelines, small LV was defined as left ventricular end-diastolic dimension <42.0 mm for men or <37.8 mm for women. The 2-year clinical outcomes were compared between patients with and without small LV using multivariable Cox regression analyses and propensity score matching. Subgroup analyses by LF, left ventricular hypertrophy were performed. Of 2584 patients who underwent TAVR, 466 (18.0%) had small LV. Patients with small LV had smaller body size and less comorbidity, and were more likely to have LF status compared with those without. Small LV was associated with a higher 2-year all-cause (20.8% versus 14.3%; adjusted hazard ratio [HR],1.58 [95% CI, 1.20–2.09]; P=0.0013) and cardiovascular mortality (8.8% versus 5.5%; adjusted HR, 1.93 [95% CI, 1.25–2.98]; P=0.0028). Propensity score matching analysis showed consistent findings. In subgroup analyses, LF, left ventricular hypertrophy did not interact with small LV. CONCLUSIONS: Small LV, determined by a simple echocardiographic parameter, was associated with poorer clinical outcomes after TAVR regardless of LF, left ventricular hypertrophy. LV size may be useful for assessing clinical outcomes after TAVR.
KW - Heart failure
KW - Left ventricular end-diastolic dimension
KW - Left ventricular hypertrophy
KW - Propensity score matching
KW - Transcatheter aortic valve replacement
UR - http://www.scopus.com/inward/record.url?scp=85104047363&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85104047363&partnerID=8YFLogxK
U2 - 10.1161/JAHA.120.019543
DO - 10.1161/JAHA.120.019543
M3 - Article
C2 - 33749309
AN - SCOPUS:85104047363
SN - 2047-9980
VL - 10
JO - Journal of the American Heart Association
JF - Journal of the American Heart Association
IS - 7
M1 - e019543
ER -